Compare iShares MSCI South Korea ETF (EWY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI South Korea ETF trades at $178.31 (market cap $26.77B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.8× iShares MSCI South Korea ETF's market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (806,603 versus 12,180,040). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWY | VRTX | |
|---|---|---|
Market Cap | $26.77B | $128.16B |
Volume | 12,180,040 | 806,603 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $557.96 |
52-Week Low | $80.72 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) trades at $183.72, down 1.44% amid mixed technical signals with neutral overall momentum. The ETF faces pressure from rising oil prices and global bond yields impacting South Korean semiconductor stocks, though AI-driven demand provides underlying support. Recent volatility around the 7,000 KOSPI level reflects ongoing tension between technology sector strength and macroeconomic headwinds.
Outlook remains cautiously optimistic given South Korea's strong corporate earnings and AI infrastructure growth, but concentrated exposure to Samsung and SK hynix creates sensitivity to memory cycle fluctuations. Key risks include persistent inflation pressures and global semiconductor demand volatility that could challenge near-term performance despite long-term AI tailwinds.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
